Rapport Therapeutics, Inc. Share Price

Rapport Therapeutics, Inc. Share Price

NASDAQ: RAPP | Small Cap
$24.18
+$1.71 (7.61%) Last updated on 30 Oct, 2026 | 01:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Rapport Therapeutics, Inc. Stock Performance

Open
$22.80
Prev. Close
$22.47
Circuit Range
N/A
Day Range
$22.80 - $25.75
Year Range
$22.08 - $52.93
Volume
1,73,155
Average Traded
$24.40

Rapport Therapeutics, Inc. Share Price Today

As of 30 October 2026, Rapport Therapeutics, Inc.'s share price is $24.18. The stock opened at $22.80, compared to its previous close of $22.47. During today's trading session, Rapport Therapeutics, Inc.'s share price traded between $22.80 and $25.75, with an average price of $24.27. Over the past 52 weeks, the stock has recorded a high of $52.93 and a low of $22.08. In terms of performance, Rapport Therapeutics, Inc.'s share price has declined by 27.08% over the last six months and is down 16.32% on a year-on-year basis.

Rapport Therapeutics, Inc. Share Price Chart

Line chart of the Rapport Therapeutics, Inc. price trend over the selected period. The price rose overall, ranging from 22.80 to 25.75, ending at 24.15.
$22.80$25.75
L
Show Current Price
H

Rapport Therapeutics, Inc. Stock Fundamentals & Key Indicators

Market Cap
$941.44M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-2.86
Revenue (TTM)
$0.00
Return On Equity (TTM)
-32.43%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
-110.25%

Rapport Therapeutics, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.00$0.00$20.00$0.00
Net Profit-$26.93-$33.76-$19.86-$56.62
Net Profit MarginN/AN/A-99.30%N/A
Income ChangeN/A-25.36%41.17%-185.10%

Rapport Therapeutics, Inc. Annual Profit & Loss

All figures in USD

Particulars20242025
Revenue$0.00$0.00
Net Profit-$78.31-$111.48
Net Profit MarginN/AN/A
Income ChangeN/A-42.36%

About Rapport Therapeutics, Inc.

Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Rapport Therapeutics, Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$34.00
$24.16
-28.10%
Sep 2026
$48.88
$33.61
-33.96%
Aug 2026
$40.13
$50.89
+23.94%
Jul 2026
$41.12
$41.06
-1.65%
Jun 2026
$37.98
$41.75
+5.72%
May 2026
$32.84
$39.49
+19.09%
Apr 2026
$31.58
$33.16
+5.40%
Mar 2026
$28.41
$31.46
+8.56%
Feb 2026
$26.99
$28.98
+8.99%
Jan 2026
$30.08
$26.59
-12.40%
Dec 2025
$28.92
$30.36
+2.48%
Nov 2025
$29.13
$29.62
+2.51%

RAPP Share Price FAQs